Amicus Therapeutics is one of the rapidly growing companies in Pharmaceutical. Its less dominated line of trade is partly the reason it has made that far. Amicus Therapeutics deals with atypical diseases and disorders more so among orphans. Their area of specialty is in lysosomal storage disorders, Fabry and Pompe disease and the Epidermolysis Bullosa (EB) which is a genetically inherited skin disorder.
Although rare disease remains a largely unexplored area in science, some medical companies such as Amicus Therapeutics are giving their all to comprehend this complexity (Crunchbase). Amicus Therapeutics is motivated by the vision of making a positive difference in the life and quality of life of patients and easier management by the medical personnel. Research and experiments, fortunately, have to lead to the development of a reliable product migalastat. It is for use by patients with Fabry disease after thorough diagnosis. Amicus collaborated with JCR AND GlaxoSmithKline Pharmaceutical since Amicus Therapeutics cannot manufacture drugs in the development of migalastat.
The personalized treatment alternatives are developed in line with Chaperone-Advanced Replacement Therapy (CHART™) and ATB200/AT2221, a program in biologics. The $ 500,000 grant from Michael J. Fox Foundation for medical studies at UCLA- School of Medicine and the $210,300 for Alzheimer’s Drug Discovery has helped bridge some clinical gaps of information.
About Amicus Therapeutics
It was established on 4th February 2002 in Cranbury, New Jersey. Amicus Therapeutics is a publicly listed biopharmaceutical company in the securities market. Its NASDAQ trading symbol is FOLD since its listing in 2007. Before publicly trading its stock, Amicus Therapeutics was being funded by a financial institution such as Raduis Ventures, Canaan Partners, and New Enterprise Associate.
In the executive leadership is John F. Crowley who succeeded Donald Hayden in 2005 as Chief Executive Officer (https://forexwizard.biz/2017/09/15/amicus-therapeutics/). Other significant personnel includes Bradley Campbell – Chief Operating Officer, William Baird – Chief Financial Officer and David Lockhart as Chief Scientific Officer.
As an expansion strategy, Amicus Therapeutics acquired Callidus Biopharma in 2013 for ERTs treatment of Pompe disease. In 2015, Scioderm was acquired for $947 million both for stock and cash. They have helped boost clinical treatment for the rare condition.